Competitor Analysis: EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux
Competitor Analysis: EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux
This Competitive Intelligence Report about EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence Report about EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
2014 Sales of EGF-R Antibodies
br>Marketed EGF-R Antibodies
Erbitux Sales & Pipeline
Vectibix Sales & Pipeline
Nimotuzumab Pipeline
EGF-R Antibody Biosuperiors
Engineered EGF-R Antibodies
Bi- and Multispecific EGF-R Antibodies
EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
Cetuximab Biosimilars
Corporate Biosuperior & Biosimilar EGF-R Antibody Pipelines
br>Marketed EGF-R Antibodies
Erbitux Sales & Pipeline
Vectibix Sales & Pipeline
Nimotuzumab Pipeline
EGF-R Antibody Biosuperiors
Engineered EGF-R Antibodies
Bi- and Multispecific EGF-R Antibodies
EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
Cetuximab Biosimilars
Corporate Biosuperior & Biosimilar EGF-R Antibody Pipelines
More Publications
Competitor Analysis: EGF-R Agonists and Antagonists
US$ 533.00
September 2011
73 pages
Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab
US$ 346.00
March 2015
62 pages
Competitor Analysis: Biosimilar and Biobetter/Biosuperior Antibodies
US$ 961.00
October 2010
106 pages
Competitor Analysis: Antibody-Drug Conjugates (ADC)
US$ 785.00
April 2013
104 pages
Competitor Analysis: Cancer Antibodies in Early Clinical Development
US$ 1,210.00
February 2011
183 pages
